Seven months into the year, there were already four reported deals valued at over $1 billion in 2023, as many as in all of 2022.
Subscribe today for access to
Articles and Reports
Diagnostics companies that invested heavily in COVID-19 products are relying on M&A transactions to restructure and transition.
The recent FDA approval of an OTC test shows that COVID-19 saliva testing may be poised for bigger and better things in the years ahead.
Though only seven transactions were announced or closed in November, two were billion-dollar deals.
Increasing incidences of heart disease, as well as technological advances, will drive growth over the next eight to 10 years, reports say.
Continuing recent patterns, M&A deal-making in the diagnostics space was low in volume but high in impact in October.
While the overall M&A market has been slow in 2022, Labcorp has been on a bit of an acquisitions binge.
It’s beginning to look like Illumina’s roll of the dice is going to come up snake eyes regarding the potential acquisition.
Two of the biggest merger and acquisition-related deals that came down in May involved BioMérieux and Sema4
Companies are using the lessons learned from COVID-19 to get out of the box quickly in developing test kits for monkeypox.
According to a recent report, this market will see almost seven percent annual growth over the next five years, reaching US $1.29 billion in 2026.